NeoGenomics (NEO)
Market Price (9/29/2026): $19.08 | Market Cap: $2.5 BilSector: Health Care | Industry: Health Care Services
NeoGenomics (NEO)
Market Price (9/29/2026): $19.08Market Cap: $2.5 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Trading close to highsDist 52W High is -3.1% Weak multi-year price returns2Y Excs Rtn is -12%, 3Y Excs Rtn is -19% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.18, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -61 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.9% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 113x Stock price has recently run up significantly6M Rtn6 month market price return is 168%, 12M Rtn12 month market price return is 143% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 154% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.0% Key risksNEO key risks include [1] persistent unprofitability and declining margins, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Trading close to highsDist 52W High is -3.1% |
| Weak multi-year price returns2Y Excs Rtn is -12%, 3Y Excs Rtn is -19% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.18, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -61 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.9% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 113x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 168%, 12M Rtn12 month market price return is 143% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 154% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.0% |
| Key risksNEO key risks include [1] persistent unprofitability and declining margins, Show more. |
Qualitative Assessment
AI Analysis | Feedback
NeoGenomics (NEO) stock has gained about 85% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Raised Guidance.
NeoGenomics reported adjusted earnings per share (EPS) of $0.05 for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analysts' consensus estimates of $0.03 by 49%. Total revenue reached $201.66 million, surpassing expectations of $196.93 million and marking an 11.2% increase year-over-year. This robust performance led management to raise its full-year 2026 revenue and adjusted EBITDA guidance, signaling continued positive momentum. The company also achieved a net income of $2 million in fiscal Q2 2026, a substantial improvement from a net loss of $45 million in the prior-year period.
2. Robust Growth in Next-Generation Sequencing (NGS) and Precision Oncology Focus.
The company demonstrated strong growth in its higher-value Next-Generation Sequencing (NGS) offerings, with NGS revenue increasing 26% year-over-year in fiscal Q2 2026. This drove an overall 12% increase in average revenue per clinical test to $515. NeoGenomics has strategically shifted its focus toward high-value precision oncology segments, including NGS, minimal residual disease (MRD) testing, and liquid biopsy solutions. The ongoing commercial launch of PanTracer, a comprehensive liquid biopsy panel, is anticipated to further enhance the company's competitive position and market share in these rapidly expanding diagnostic areas.
Show more
NeoGenomics (NEO) stock has gained about 85% since 5/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat and Raised Guidance.
NeoGenomics reported adjusted earnings per share (EPS) of $0.05 for fiscal Q2 2026 (ended June 30, 2026), significantly exceeding analysts' consensus estimates of $0.03 by 49%. Total revenue reached $201.66 million, surpassing expectations of $196.93 million and marking an 11.2% increase year-over-year. This robust performance led management to raise its full-year 2026 revenue and adjusted EBITDA guidance, signaling continued positive momentum. The company also achieved a net income of $2 million in fiscal Q2 2026, a substantial improvement from a net loss of $45 million in the prior-year period.
2. Robust Growth in Next-Generation Sequencing (NGS) and Precision Oncology Focus.
The company demonstrated strong growth in its higher-value Next-Generation Sequencing (NGS) offerings, with NGS revenue increasing 26% year-over-year in fiscal Q2 2026. This drove an overall 12% increase in average revenue per clinical test to $515. NeoGenomics has strategically shifted its focus toward high-value precision oncology segments, including NGS, minimal residual disease (MRD) testing, and liquid biopsy solutions. The ongoing commercial launch of PanTracer, a comprehensive liquid biopsy panel, is anticipated to further enhance the company's competitive position and market share in these rapidly expanding diagnostic areas.
3. Positive Regulatory Milestones for RaDaR ST Minimal Residual Disease (MRD) Testing.
On August 26, 2026, NeoGenomics received a significant boost with Medicare coverage approval for its RaDaR ST minimal residual disease (MRD) test for immunotherapy treatment response monitoring. This regulatory milestone expanded the addressable market for the RaDaR ST MRD test by approximately $4 billion, out of an estimated total MRD market of $20 billion, considerably broadening its commercial opportunities. The company also submitted additional evidence for RaDaR ST to MolDx for a new indication, further solidifying its presence in the MRD testing landscape.
4. Favorable Analyst Sentiment and Price Target Upgrades.
Throughout the period, NeoGenomics saw a noticeable improvement in analyst sentiment, with several firms upgrading their ratings and increasing price targets. For instance, Wall Street Zen upgraded NeoGenomics from a "hold" to a "buy" rating on June 27, 2026. Benchmark raised its price objective from $11.00 to $16.00 with a "buy" rating on July 24, 2026, and Craig Hallum reiterated a "buy" rating with a $19.00 price objective on July 29, 2026. The current consensus rating for the stock is a "Moderate Buy" or "Strong Buy," with average price targets ranging from $17.67 to $19.72, indicating continued analyst confidence in the company's prospects.
Show less
Stock Movement Drivers
Fundamental Drivers
The 83.4% change in NEO stock from 5/31/2026 to 9/28/2026 was primarily driven by a 79.1% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9282026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.52 | 19.29 | 83.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 746 | 766 | 2.7% |
| P/S Multiple | 1.8 | 3.3 | 79.1% |
| Shares Outstanding (Mil) | 129 | 130 | -0.4% |
| Cumulative Contribution | 83.4% |
Market Drivers
5/31/2026 to 9/28/2026| Return | Correlation | |
|---|---|---|
| NEO | 83.4% | |
| Market (SPY) | 1.5% | 13.7% |
| Sector (XLV) | 15.1% | 23.2% |
Fundamental Drivers
The 96.2% change in NEO stock from 2/28/2026 to 9/28/2026 was primarily driven by a 87.7% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9282026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.83 | 19.29 | 96.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 727 | 766 | 5.4% |
| P/S Multiple | 1.7 | 3.3 | 87.7% |
| Shares Outstanding (Mil) | 129 | 130 | -0.8% |
| Cumulative Contribution | 96.2% |
Market Drivers
2/28/2026 to 9/28/2026| Return | Correlation | |
|---|---|---|
| NEO | 96.2% | |
| Market (SPY) | 12.2% | 26.8% |
| Sector (XLV) | 7.8% | 30.4% |
Fundamental Drivers
The 119.7% change in NEO stock from 8/31/2025 to 9/28/2026 was primarily driven by a 100.2% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9282026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.78 | 19.29 | 119.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 689 | 766 | 11.2% |
| P/S Multiple | 1.6 | 3.3 | 100.2% |
| Shares Outstanding (Mil) | 128 | 130 | -1.3% |
| Cumulative Contribution | 119.7% |
Market Drivers
8/31/2025 to 9/28/2026| Return | Correlation | |
|---|---|---|
| NEO | 119.7% | |
| Market (SPY) | 20.0% | 23.9% |
| Sector (XLV) | 26.8% | 31.5% |
Fundamental Drivers
The 28.3% change in NEO stock from 8/31/2023 to 9/28/2026 was primarily driven by a 38.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312023 | 9282026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.03 | 19.29 | 28.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 552 | 766 | 38.9% |
| P/S Multiple | 3.4 | 3.3 | -4.5% |
| Shares Outstanding (Mil) | 125 | 130 | -3.3% |
| Cumulative Contribution | 28.3% |
Market Drivers
8/31/2023 to 9/28/2026| Return | Correlation | |
|---|---|---|
| NEO | 28.3% | |
| Market (SPY) | 76.5% | 30.6% |
| Sector (XLV) | 35.2% | 27.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NEO Return | -37% | -73% | 75% | 2% | -29% | 64% | -64% |
| Peers Return | 33% | -34% | 3% | -1% | 44% | 24% | 59% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| NEO Win Rate | 33% | 17% | 58% | 42% | 42% | 78% | |
| Peers Win Rate | 65% | 35% | 47% | 50% | 53% | 58% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| NEO Max Drawdown | -49% | -82% | -41% | -27% | -74% | -46% | |
| Peers Max Drawdown | -25% | -43% | -32% | -29% | -33% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: LH, DGX, GH, MYGN, TMO. See NEO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/28/2026 (YTD)
How Low Can It Go
| Event | NEO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -49.7% | -18.8% |
| % Gain to Breakeven | 98.9% | 23.1% |
| Time to Breakeven | 251 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -29.9% | -9.5% |
| % Gain to Breakeven | 42.6% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.5% | -33.7% |
| % Gain to Breakeven | 68.1% | 50.9% |
| Time to Breakeven | 112 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.2% | -19.2% |
| % Gain to Breakeven | 30.2% | 23.8% |
| Time to Breakeven | 16 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -11.8% | -3.7% |
| % Gain to Breakeven | 13.3% | 3.9% |
| Time to Breakeven | 1 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -12.3% | -12.2% |
| % Gain to Breakeven | 14.0% | 13.9% |
| Time to Breakeven | 17 days | 62 days |
In The Past
NeoGenomics's stock fell -49.7% during the 2025 US Tariff Shock. Such a loss loss requires a 98.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | NEO | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -49.7% | -18.8% |
| % Gain to Breakeven | 98.9% | 23.1% |
| Time to Breakeven | 251 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -29.9% | -9.5% |
| % Gain to Breakeven | 42.6% | 10.5% |
| Time to Breakeven | 35 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.5% | -33.7% |
| % Gain to Breakeven | 68.1% | 50.9% |
| Time to Breakeven | 112 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -23.2% | -19.2% |
| % Gain to Breakeven | 30.2% | 23.8% |
| Time to Breakeven | 16 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -33.2% | -6.8% |
| % Gain to Breakeven | 49.7% | 7.3% |
| Time to Breakeven | 126 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -39.7% | -0.2% |
| % Gain to Breakeven | 65.7% | 0.2% |
| Time to Breakeven | 65 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -27.3% | -17.9% |
| % Gain to Breakeven | 37.6% | 21.8% |
| Time to Breakeven | 35 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -26.1% | -15.4% |
| % Gain to Breakeven | 35.2% | 18.2% |
| Time to Breakeven | 181 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -46.2% | -53.4% |
| % Gain to Breakeven | 85.7% | 114.4% |
| Time to Breakeven | 77 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -30.0% | -8.6% |
| % Gain to Breakeven | 42.9% | 9.5% |
| Time to Breakeven | 714 days | 47 days |
In The Past
NeoGenomics's stock fell -49.7% during the 2025 US Tariff Shock. Such a loss loss requires a 98.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NeoGenomics (NEO)
NeoGenomics, Inc. (NEO) is a specialized oncology testing company that operates a global network of cancer-focused laboratories across the United States, Europe, and Asia. The company primarily provides comprehensive diagnostic and prognostic testing services tailored for various cancer types, serving both clinical and pharmaceutical clients.
Through its Clinical Services segment, NeoGenomics offers a wide array of sophisticated testing methodologies, including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC), and molecular testing. These services analyze chromosomes, DNA, RNA, cellular proteins, and cell populations to aid in cancer diagnosis, prognosis, and treatment decisions. Additionally, its Pharma Services segment supports pharmaceutical companies by providing testing services throughout their oncology drug discovery and commercialization processes.
NeoGenomics' diverse customer base includes hospitals, reference laboratories, pathologists, oncologists, and other clinicians who rely on its precise diagnostic insights. Furthermore, the company partners with pharmaceutical firms and researchers, offering crucial laboratory support for the development and advancement of new cancer therapies.
AI Analysis | Feedback
NeoGenomics is like the LabCorp or Quest Diagnostics specifically for advanced cancer testing.
Think of NeoGenomics as a 'forensic lab' for cancer, uncovering critical biological clues for doctors and drug developers.
AI Analysis | Feedback
- Cytogenetics Testing: Services that study normal and abnormal chromosomes and their relationship to diseases.
- Fluorescence In-Situ Hybridization (FISH) Testing: Services for detecting and locating specific DNA sequences and genes on chromosomes.
- Flow Cytometry Testing: Services that measure the characteristics of cell populations for diagnostic purposes.
- Immunohistochemistry (IHC) & Digital Imaging: Services to localize cellular proteins in tissue sections, along with digital slide visualization and quantitative analysis.
- Molecular Testing: Services focused on the analysis of DNA/RNA and the structure and function of genes at the molecular level.
- Morphologic Analysis: Pathologist-led analysis of cells under a microscope for diagnostic purposes.
- Anatomic Pathology Reference Services: Comprehensive anatomic pathology testing services provided as a reference laboratory.
- Pharmaceutical Oncology Support Services: Testing and support services for pharmaceutical clients' oncology programs, spanning discovery through commercialization.
AI Analysis | Feedback
NeoGenomics (NEO) sells primarily to other companies and organizations, rather than directly to individuals. Based on the provided description, its major customers fall into the following categories:
- Hospitals
- Reference labs
- Pathologists
- Oncologists
- Clinicians
- Pharmaceutical firms
- Researchers
AI Analysis | Feedback
Major Suppliers:
- Roche (RHHBY)
- Thermo Fisher Scientific (TMO)
- Abbott Laboratories (ABT)
AI Analysis | Feedback
Tony Zook, Chief Executive Officer
Tony Zook became CEO of NeoGenomics in April 2025. Prior to his appointment as CEO, he served on NeoGenomics' Board of Directors for two years, chairing the Compensation Committee and serving on the Audit and Technology committees. He brings extensive experience as a brand and marketing executive, focusing on the intersection of commercial and research and development within organizations. Previously, Mr. Zook was the Chief Executive Officer of Innocoll Biotherapeutics. He also held the role of Executive Vice President, Commercial Operations at AstraZeneca (AZ), where he was responsible for global profit and loss for all of AZ's brands and markets, overseeing the commercialization of 10 brands, each exceeding $1 billion in sales. At AZ, he was also responsible for MedImmune, the global biologics business, and chaired the Commercial Investment Board. Earlier in his career at AZ, he held positions including CEO of North America and VP of Sales, and was involved in the integrations of Astra US, Astra Merck, and Zeneca. Mr. Zook spent 14 years with Berlex Laboratories in various roles.
Abhishek Jain, Chief Financial Officer
Abhishek Jain joined NeoGenomics as Executive Vice President on January 12, 2026, and officially transitioned to Chief Financial Officer on March 2, 2026. He possesses over 25 years of global finance and operational leadership experience across the life sciences and diagnostics sectors. Most recently, he served as Chief Financial Officer at CareDx from September 2022 to August 2025, where he was instrumental in guiding the company back to profitable growth, enhancing financial discipline, and strategically allocating resources for long-term value creation. Prior to CareDx, Mr. Jain spent nearly two decades at Agilent Technologies, progressing through various global finance and operational leadership positions. His roles at Agilent included Global Controller for the company's sales and marketing organization, managing a $5 billion orders portfolio, and Head of Agilent Corporate. Mr. Jain is a Certified Public Accountant (inactive) and a Chartered Accountant from the Institute of Chartered Accountants of India.
Warren Stone, President and Chief Operating Officer
Warren Stone was appointed President and Chief Operating Officer of NeoGenomics in April 2025. He joined the company in November 2022 as President, Clinical Services, and was later promoted to Chief Commercial Officer in April 2024. Mr. Stone is recognized as a highly accomplished enterprise leader with extensive global experience in the life science and diagnostic sectors. Before joining NeoGenomics, he served as President of Americas at Ortho Clinical Diagnostics (now QuidelOrtho) and as Senior Vice President at MilliporeSigma. He has over 25 years of experience in general management and cross-functional commercial roles.
Elizabeth Floegel, Chief Digital and Information Officer
Elizabeth Floegel serves as the Chief Digital and Information Officer at NeoGenomics. She brings significant experience in leading digital transformation and technology innovation within the healthcare industry. In her role, Ms. Floegel is crucial in advancing NeoGenomics' digital strategy, utilizing AI and automation to enhance operational efficiency and improve outcomes. Prior to her current position, she was a member of NeoGenomics' Board of Directors, where she served on the Audit and Compliance Committees.
Gary Passman, Chief Culture Officer
Gary Passman is the Chief Culture Officer at NeoGenomics, where he is responsible for the company's strategy concerning its people and fostering an engaging culture that supports all teammates and customers. He holds a Bachelor of Arts in economics and a Master's degree in human resource management from Rutgers University. Mr. Passman joined NeoGenomics in 2008 as Director of Human Resources, was appointed Vice President, Human Resources in 2015, and became Chief Culture Officer in 2016.
AI Analysis | Feedback
The key risks to NeoGenomics (NEO) include:
- Financial Health and Profitability Challenges: NeoGenomics is currently operating at a loss, with declining gross margins and inconsistent revenue growth over the past five years. The company's Altman Z-Score also indicates a potential risk of financial distress. High debt levels further increase financial risk, as the company's debt exceeds its cash on the balance sheet. This ongoing unprofitability and financial pressure can limit the company's ability to invest in growth initiatives.
- Intense Competition and Technology Adoption: The oncology diagnostic market is highly competitive and rapidly evolving, particularly in next-generation sequencing (NGS) and liquid biopsy. NeoGenomics faces significant competition from well-established players and emerging companies like Guardant Health and Natera, who possess large financial resources and aggressive sales strategies. The company has previously faced challenges in offering the most technologically advanced NGS tests, which led to a decrease in revenue as customers sought testing elsewhere. Continuous innovation and successful commercialization of new products, such as the RaDaR ST assay, are crucial to maintain and gain market share.
- Regulatory and Reimbursement Risks: As a company in the healthcare sector, NeoGenomics is subject to a complex and evolving regulatory environment, particularly concerning Laboratory Developed Tests (LDTs). Changes in regulations could impact the company's operations and test offerings. Furthermore, the process of obtaining and maintaining adequate reimbursement for specialized molecular diagnostic panels can be challenging, leading to payment bottlenecks, delays, or lower-than-expected payments from insurers and Medicare. While NeoGenomics recently secured Medicare coverage for its PanTracer LBx test, the broader risk of reimbursement complexities remains a significant factor influencing revenue and profitability.
AI Analysis | Feedback
AI Analysis | Feedback
NeoGenomics, Inc. operates in several significant addressable markets within cancer diagnostics across the globe and specifically in the U.S.
Oncology Molecular Diagnostics (including Molecular Testing)
- The global oncology molecular diagnostics market size is projected to reach approximately USD 7.11 billion by 2034. Another estimate places the global market at around USD 10.93 billion by 2035, growing from USD 3.90 billion in 2026.
- In 2024, the global oncology molecular diagnostics market was valued at USD 3.75 billion, with projections to reach USD 6.35 billion by 2030.
- The U.S. oncology molecular diagnostics market is anticipated to grow from USD 810 million in 2024 to USD 2.57 billion by 2034.
- North America is a dominant region in the global oncology molecular diagnostics market, holding a 44.69% revenue share in 2024.
Immunohistochemistry (IHC) Testing
- The global immunohistochemistry market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 3.50 billion by 2030.
- Other estimates for the global market size include USD 4.11 billion by 2033 and USD 5.11 billion by 2030, growing from USD 3.55 billion in 2025.
- North America held the largest revenue share in the global immunohistochemistry market in 2024, with over 37.77%.
Flow Cytometry Testing
- The global flow cytometry market size was estimated at USD 4.68 billion in 2024 and is projected to reach USD 7.01 billion by 2030.
- Another report values the global market at USD 6.40 billion in 2024, expected to reach USD 14.71 billion by 2032.
- North America dominated the flow cytometry market in 2024 with a 41.35% revenue share.
Molecular Cytogenetics (including Cytogenetics and FISH Testing)
- The global molecular cytogenetics market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033.
- The global molecular cytogenetics market is also projected to grow from USD 1.78 billion in 2026 to USD 3.67 billion by 2034.
- North America held the dominant share of the global molecular cytogenetics market in 2024. The U.S. market is estimated to reach USD 0.64 billion in 2026.
Fluorescence In Situ Hybridization (FISH) Testing
- The global fluorescent in situ hybridization (FISH) market size was valued at USD 1.14 billion in 2024 and is expected to reach USD 2.14 billion by 2032.
- The global molecular FISH testing market was valued at US$ 731.4 million in 2023 and is projected to hit US$ 1.37 billion by 2032.
- The global market for FISH in cancer diagnostics is anticipated to reach USD 2.5 billion by 2025.
Solid Tumor MRD (Minimal Residual Disease) Cancer Monitoring
- NeoGenomics is entering a rapidly growing solid tumor MRD cancer monitoring market, which is estimated to be over $20 billion.
Overall Cancer Diagnostics Market
- The global cancer diagnostics market size was valued at USD 17.24 billion in 2025 and is projected to grow to USD 38.27 billion by 2034.
- Another estimate places the global cancer diagnostics market size at USD 110.11 billion in 2024, expected to reach USD 199.32 billion by 2032.
- North America held the largest share of the global cancer diagnostics market in 2025, at 36.81%.
Cancer-focused Genetic Testing Services
- The global cancer-focused genetic testing service market size is likely to reach USD 8.47 billion by 2024 and is projected to reach USD 19.3 billion by the end of 2034.
- The global market size was valued at USD 7.78 billion in 2023 and is expected to exceed USD 16.51 billion by 2033.
AI Analysis | Feedback
NeoGenomics (NASDAQ: NEO) anticipates several key drivers to fuel its revenue growth over the next 2-3 years:
- New Product Launches and Adoption: The company expects significant revenue growth from the full clinical launch and adoption of its RaDaR ST minimal residual disease (MRD) assay, particularly from 2027 onwards, addressing a rapidly growing market. Additionally, the continued adoption of the PanTracer family (Tissue, Liquid, Pro) for therapy selection is projected to be a key contributor to growth.
- Increased Adoption of High-Value Clinical Testing: NeoGenomics is strategically shifting its focus towards higher-value, therapy-guided testing, including Next-Generation Sequencing (NGS), which has demonstrated strong growth rates (23% in Q4 2025 and 22% for full-year 2025). This shift is expected to drive Average Unit Price (AUP) expansion, which management forecasts as the primary revenue driver.
- Sales Force Expansion: To support the uptake of new products and indications, NeoGenomics plans to expand its sales force from 140 to approximately 165 representatives by the end of the year.
- Payer Coverage Expansion and Reimbursement Initiatives: Securing timely reimbursement approvals, especially MolDX coverage for PanTracer Liquid and broader RaDaR indications, is critical for sustained momentum. The company's strategic reimbursement initiatives and managed care pricing increases are already contributing to higher average revenue per clinical test.
- Operational Efficiencies and Technology Upgrades: Benefits from the implementation of a single Laboratory Information Management System (LIMS) are anticipated to become more pronounced in 2027 and 2028. Furthermore, the utilization of automation and artificial intelligence (AI) is expected to enhance operational efficiencies and contribute to gross margin expansion.
AI Analysis | Feedback
Outbound Investments
- NeoGenomics completed the acquisition of Pathline, LLC in March 2025, expanding its commercial presence in the Northeast U.S. and enhancing its oncology testing services, particularly in molecular and hematology-oncology testing.
- In January 2020, NeoGenomics acquired the Oncology Division assets of Human Longevity, Inc. for $37 million, which significantly enhanced its Next Generation Sequencing capabilities for pharmaceutical customers.
- NeoGenomics has a history of growth through acquisitions, with 2 acquisitions in 2021 and an average of 0.6 acquisitions per year between 2020 and 2025.
Inbound Investments
- Institutional investors have made significant investments, with FIRST LIGHT ASSET MANAGEMENT, LLC adding over 3 million shares in Q3 2025 (estimated at $23.78 million) and MILLENNIUM MANAGEMENT LLC adding over 2.6 million shares in Q3 2025 (estimated at $20.5 million).
- BlackRock, Inc. held a substantial stake in NeoGenomics as of late 2025.
Capital Expenditures
- Capital expenditures were approximately $27 million in 2025, $41 million in 2024, $29 million in 2023, and $19 million in 2022.
- In the most recent 12 months, capital expenditures were -$27.01 million.
- The company's capital expenditures in the most recent quarter totaled -$8.31 million.
Peer Outperformance in Health Care Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| NEO | NeoGenomics | 11.6% | -48.2x | 143.3% | 56.8% | -60.5% | — |
| RDNT | RadNet | 14.1% | -264.5x | -5.4% | 154.7% | 142.8% | +203pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 6.4% | 44.5% | 85.7% | CAH 376% · MCK 327% · COR 161% |
| Health Care Services ← | 20 | 19.3% | 36.2% | 5.5% | HIMS 282% · RDNT 143% · DGX 77% |
| Managed Health Care | 8 | 30.8% | -7.0% | 3.4% | OSCR 69% · HQY 32% · ELV 9% |
| Health Care Facilities | 24 | 2.4% | 7.1% | -2.7% | THC 276% · NHC 260% · ENSG 137% |
| Health Care Equipment | 50 | -0.1% | -0.8% | -15.8% | POCI 11213% · UFPT 377% · GKOS 225% |
| Pharmaceuticals | 63 | -5.2% | 3.1% | -36.6% | LQDA 2541% · INDV 1125% · ETON 1074% |
| Health Care Supplies | 12 | 27.3% | -7.0% | -37.6% | LNTH 287% · HAE 50% · MMSI 21% |
| Life Sciences Tools & Services | 113 | -1.0% | -11.7% | -65.0% | SNWV 1798% · NTRA 283% · MEDP 228% |
| Health Care Technology | 21 | -27.8% | -50.9% | -73.0% | SPOK 72% · HSTM 3% · VEEV -1% |
| Biotechnology | 373 | -10.0% | -25.4% | -78.4% | CELZ 1343% · DNTH 1123% · ELVN 1028% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| NeoGenomics Earnings Notes | 12/16/2025 | |
| Would You Still Hold NeoGenomics Stock If It Fell 30%? | 10/17/2025 | |
| Day 5 of Gains Streak for NeoGenomics Stock with 37% Return (vs. -47% YTD) [9/2/2025] | 09/03/2025 | |
| NeoGenomics (NEO) Operating Cash Flow Comparison | 08/08/2025 | |
| NeoGenomics (NEO) Net Income Comparison | 08/08/2025 | |
| NeoGenomics (NEO) EBITDA Comparison | 08/08/2025 | |
| NeoGenomics (NEO) Revenue Comparison | 08/08/2025 | |
| NeoGenomics (NEO) Debt Comparison | 08/08/2025 | |
| NeoGenomics (NEO) Tax Expense Comparison | 08/08/2025 | |
| NeoGenomics (NEO) Operating Income Comparison | 08/08/2025 | |
| ARTICLES | ||
| Small Cap Stocks At 52-Week Highs: Friday’s Full List | 09/21/2026 | |
| 15 Small Cap Stocks Just Made New 52-Week Highs | 09/17/2026 | |
| NEO Stock Up 37% after 5-Day Win Streak | 09/02/2025 | |
| Market Movers | Winners: WOOF, NEO, AMBA | Losers: MRVL, UP, AEVA | 08/29/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 205.50 |
| Mkt Cap | 24.3 |
| Rev LTM | 6,372 |
| Op Inc LTM | 784 |
| FCF LTM | 574 |
| FCF 3Y Avg | 536 |
| CFO LTM | 830 |
| CFO 3Y Avg | 792 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.5% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 10.4% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Inc Chg LTM | 9.2% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 1.7% |
| Op Mgn 3Y Avg | -0.7% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 7.1% |
| CFO/Rev 3Y Avg | 6.7% |
| FCF/Rev LTM | 3.5% |
| FCF/Rev 3Y Avg | 2.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 24.3 |
| P/S | 2.7 |
| P/Op Inc | 5.5 |
| P/EBIT | 5.7 |
| P/E | 10.5 |
| P/CFO | 21.6 |
| Total Yield | 0.6% |
| Dividend Yield | 0.1% |
| FCF Yield 3Y Avg | 1.3% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.1% |
| 3M Rtn | 12.7% |
| 6M Rtn | 30.6% |
| 12M Rtn | 36.3% |
| 3Y Rtn | 56.3% |
| 1M Excs Rtn | 3.9% |
| 3M Excs Rtn | 9.5% |
| 6M Excs Rtn | 11.6% |
| 12M Excs Rtn | 22.1% |
| 3Y Excs Rtn | -21.4% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single Segment | 727 | 661 | 592 | 510 | |
| Advanced Diagnostics | 80 | ||||
| Clinical Services | 404 | ||||
| Total | 727 | 661 | 592 | 510 | 484 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Single Segment | -116 | -92 | -108 | -158 |
| Total | -116 | -92 | -108 | -158 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Single Segment | -108 | -79 | -88 | -144 |
| Total | -108 | -79 | -88 | -144 |
Price Behavior
| Market Price | $19.29 | |
| Market Cap ($ Bil) | 2.5 | |
| First Trading Date | 03/16/2004 | |
| Distance from 52W High | -3.1% | |
| 50 Days | 200 Days | |
| DMA Price | $16.88 | $12.20 |
| DMA Trend | up | up |
| Distance from DMA | 14.3% | 58.2% |
| 3M | 1YR | |
| Volatility | 53.5% | 53.2% |
| Downside Capture | 5.08 | 51.87 |
| Upside Capture | 162.68 | 145.92 |
| Correlation (SPY) | 8.3% | 24.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.86 | 0.59 | 0.73 | 1.21 | 1.07 | 1.29 |
| Up Beta | 0.26 | 2.06 | 0.76 | 1.08 | 1.55 | 1.51 |
| Down Beta | -1.31 | -6.27 | -0.47 | 0.75 | 0.35 | 0.84 |
| Up Capture | 570% | 247% | 283% | 241% | 189% | 204% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 10 | 20 | 34 | 70 | 132 | 373 |
| Down Capture | 405% | 111% | -12% | 88% | 87% | 108% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 11 | 20 | 28 | 55 | 114 | 365 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NEO | |
|---|---|---|---|---|
| NEO | 146.1% | 53.1% | 1.87 | - |
| Sector ETF (XLV) | 29.5% | 16.1% | 1.41 | 29.7% |
| Equity (SPY) | 17.4% | 13.0% | 0.96 | 24.2% |
| Gold (GLD) | 9.7% | 29.6% | 0.31 | 12.4% |
| Commodities (DBC) | 42.7% | 20.7% | 1.60 | -12.8% |
| Real Estate (VNQ) | 4.3% | 13.6% | 0.06 | 19.6% |
| Bitcoin (BTCUSD) | -23.0% | 44.8% | -0.46 | 11.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NEO | |
|---|---|---|---|---|
| NEO | -16.3% | 70.1% | 0.05 | - |
| Sector ETF (XLV) | 7.1% | 15.2% | 0.28 | 31.2% |
| Equity (SPY) | 13.5% | 17.2% | 0.60 | 38.3% |
| Gold (GLD) | 18.1% | 18.9% | 0.77 | 9.4% |
| Commodities (DBC) | 11.0% | 19.5% | 0.44 | 1.9% |
| Real Estate (VNQ) | 0.9% | 18.9% | -0.06 | 34.4% |
| Bitcoin (BTCUSD) | 14.4% | 52.4% | 0.45 | 20.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NEO | |
|---|---|---|---|---|
| NEO | 9.1% | 58.5% | 0.40 | - |
| Sector ETF (XLV) | 10.9% | 16.7% | 0.53 | 35.4% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 40.3% |
| Gold (GLD) | 11.7% | 16.4% | 0.58 | 7.8% |
| Commodities (DBC) | 8.5% | 18.1% | 0.38 | 6.6% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 33.9% |
| Bitcoin (BTCUSD) | 63.8% | 66.2% | 1.03 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 8/28/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | 14.0% | 21.6% | 29.6% |
| 4/28/2026 | -0.7% | -1.8% | 13.0% |
| 2/17/2026 | 0.5% | -12.4% | -27.3% |
| 10/28/2025 | -2.4% | -3.7% | 21.5% |
| 7/29/2025 | -18.7% | -12.2% | 3.7% |
| 4/29/2025 | -34.0% | -21.4% | -25.6% |
| 2/18/2025 | -14.0% | -22.5% | -33.4% |
| 11/5/2024 | 5.6% | 15.6% | 27.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 14 |
| # Negative | 13 | 13 | 10 |
| Median Positive | 14.2% | 15.6% | 13.1% |
| Median Negative | -3.8% | -10.2% | -20.6% |
| Max Positive | 25.4% | 54.2% | 63.1% |
| Max Negative | -34.0% | -22.5% | -34.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 7/28/2026 | 14.0% | 21.6% | 29.6% |
| 4/28/2026 | -0.7% | -1.8% | 13.0% |
| 2/17/2026 | 0.5% | -12.4% | -27.3% |
| 10/28/2025 | -2.4% | -3.7% | 21.5% |
| 7/29/2025 | -18.7% | -12.2% | 3.7% |
| 4/29/2025 | -34.0% | -21.4% | -25.6% |
| 2/18/2025 | -14.0% | -22.5% | -33.4% |
| 11/5/2024 | 5.6% | 15.6% | 27.4% |
| 7/29/2024 | 18.0% | 10.7% | 12.0% |
| 4/30/2024 | -8.5% | 1.9% | -9.1% |
| 2/20/2024 | 12.1% | 9.7% | 5.7% |
| 11/6/2023 | 14.2% | 9.8% | 24.2% |
| 8/8/2023 | -3.0% | -11.8% | -9.7% |
| 5/8/2023 | 18.5% | 24.2% | 13.2% |
| 2/23/2023 | 24.6% | 24.2% | 36.0% |
| 11/8/2022 | 25.4% | 54.2% | 63.1% |
| 8/9/2022 | 14.2% | 26.2% | 0.4% |
| 4/27/2022 | -3.8% | -9.2% | -27.6% |
| 2/23/2022 | -1.1% | 12.4% | -6.6% |
| 11/4/2021 | -17.6% | -8.1% | -34.5% |
| 8/6/2021 | -2.0% | -10.2% | 7.7% |
| 5/5/2021 | -11.8% | -18.0% | -15.7% |
| 2/24/2021 | 2.5% | -2.6% | -10.0% |
| 10/27/2020 | -1.7% | -8.9% | 7.5% |
| SUMMARY STATS | |||
| # Positive | 11 | 11 | 14 |
| # Negative | 13 | 13 | 10 |
| Median Positive | 14.2% | 15.6% | 13.1% |
| Median Negative | -3.8% | -10.2% | -20.6% |
| Max Positive | 25.4% | 54.2% | 63.1% |
| Max Negative | -34.0% | -22.5% | -34.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/28/2026 | 10-Q |
| 03/31/2026 | 04/28/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 07/30/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/28/2026 | 10-Q |
| 03/31/2026 | 04/28/2026 | 10-Q |
| 12/31/2025 | 02/17/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/18/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 07/30/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 02/24/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/09/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 10/29/2020 | 10-Q |
| 06/30/2020 | 07/31/2020 | 10-Q |
| 03/31/2020 | 04/29/2020 | 10-Q |
| 12/31/2019 | 02/28/2020 | 10-K |
| 09/30/2019 | 11/13/2019 | 10-Q |
Recent Forward Guidance
Updated 9/28/2026Latest: Q2 2026 Earnings Reported 7/28/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net loss | Reported | -42.00 Mil | -38.00 Mil | -34.00 Mil | 48.7% | Raised | Guidance: -56.50 Mil for 2026 | |
| 2026 Consolidated revenue | Reported | 802.00 Mil | 804.00 Mil | 806.00 Mil | 0.5% | Raised | Guidance: 800.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 56.00 Mil | 57.00 Mil | 58.00 Mil | 1.8% | Raised | Guidance: 56.00 Mil for 2026 | |
| 2026 Adjusted diluted EPS | Reported | 0.17 | 0.19 | 0.2 | ||||
Prior: Q1 2026 Earnings Reported 4/28/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net loss | Reported | -63.00 Mil | -56.50 Mil | -50.00 Mil | 0 | Affirmed | Guidance: -56.50 Mil for 2026 | |
| 2026 Consolidated revenue | Reported | 797.00 Mil | 800.00 Mil | 803.00 Mil | 0.4% | Raised | Guidance: 797.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 55.00 Mil | 56.00 Mil | 57.00 Mil | 0 | Affirmed | Guidance: 56.00 Mil for 2026 | |
Q4 2025 Earnings Reported 2/17/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net loss | Reported | -63.00 Mil | -56.50 Mil | -50.00 Mil | -49.6% | Higher New | Actual: -112.00 Mil for 2025 | |
| 2026 Consolidated revenue | Reported | 793.00 Mil | 797.00 Mil | 801.00 Mil | 10.2% | Higher New | Actual: 723.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | Reported | 55.00 Mil | 56.00 Mil | 57.00 Mil | 31.8% | Higher New | Actual: 42.50 Mil for 2025 | |
Q3 2025 Earnings Reported 10/28/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Net Loss | Reported | -116.00 Mil | -112.00 Mil | -108.00 Mil | 0 | Affirmed | Guidance: -112.00 Mil for 2025 | |
| 2025 Consolidated Revenue | Reported | 720.00 Mil | 723.00 Mil | 726.00 Mil | 0 | Affirmed | Guidance: 723.00 Mil for 2025 | |
| 2025 Adjusted EBITDA | Reported | 41.00 Mil | 42.50 Mil | 44.00 Mil | 0 | Affirmed | Guidance: 42.50 Mil for 2025 | |
Insider Activity
Updated 9/3/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Aunan, Greg D | Chief Accounting Officer | Direct | Sell | 8062026 | 16.07 | 20,000 | 321,400 | 82,809 | Form |
| 2 | Tetrault, Lynn A | Direct | Sell | 6172026 | 11.10 | 5,307 | 58,908 | 955,876 | Form | |
| 3 | Tetrault, Lynn A | Direct | Sell | 6112026 | 11.29 | 5,307 | 59,916 | 1,032,154 | Form | |
| 4 | Stone, Warren | Pres & Chief Operating Officer | Direct | Sell | 1212026 | 12.50 | 22,128 | 276,682 | 1,520,838 | Form |
| 5 | Olivo, Alicia C | EVP, GC & Business Development | Direct | Sell | 11282025 | 12.00 | 20,916 | 250,992 | 372,996 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Aunan, Greg D | Chief Accounting Officer | Direct | Sell | 8062026 | 16.07 | 20,000 | 321,400 | 82,809 | Form |
| 2 | Tetrault, Lynn A | Direct | Sell | 6172026 | 11.10 | 5,307 | 58,908 | 955,876 | Form | |
| 3 | Tetrault, Lynn A | Direct | Sell | 6112026 | 11.29 | 5,307 | 59,916 | 1,032,154 | Form | |
| 4 | Stone, Warren | Pres & Chief Operating Officer | Direct | Sell | 1212026 | 12.50 | 22,128 | 276,682 | 1,520,838 | Form |
| 5 | Olivo, Alicia C | EVP, GC & Business Development | Direct | Sell | 11282025 | 12.00 | 20,916 | 250,992 | 372,996 | Form |
| 6 | Olivo, Alicia C | EVP, GC & Business Development | Direct | Sell | 10202025 | 10.00 | 4,918 | 49,180 | 430,220 | Form |
Investor Activity (13F)
Updated Sep 29, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.